WO2001041781A3 - Inhibiteurs de proteine id pour le traitement de maladies oculaires - Google Patents

Inhibiteurs de proteine id pour le traitement de maladies oculaires Download PDF

Info

Publication number
WO2001041781A3
WO2001041781A3 PCT/US2000/032585 US0032585W WO0141781A3 WO 2001041781 A3 WO2001041781 A3 WO 2001041781A3 US 0032585 W US0032585 W US 0032585W WO 0141781 A3 WO0141781 A3 WO 0141781A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating ocular
ocular diseases
protein inhibitors
inhibitors
treating
Prior art date
Application number
PCT/US2000/032585
Other languages
English (en)
Other versions
WO2001041781A2 (fr
Inventor
Abbot F Clark
Joseph M Defaller
Original Assignee
Abbot F Clark
Joseph M Defaller
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbot F Clark, Joseph M Defaller, Alcon Universal Ltd filed Critical Abbot F Clark
Priority to AU19355/01A priority Critical patent/AU1935501A/en
Publication of WO2001041781A2 publication Critical patent/WO2001041781A2/fr
Publication of WO2001041781A3 publication Critical patent/WO2001041781A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors

Abstract

Cette invention concerne des compositions et des méthodes permettant de traiter une néovascularisation oculaire avec des inhibiteurs de Id-1 ou Id-3.
PCT/US2000/032585 1999-12-09 2000-11-30 Inhibiteurs de proteine id pour le traitement de maladies oculaires WO2001041781A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19355/01A AU1935501A (en) 1999-12-09 2000-11-30 Id protein inhibitors for treating ocular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16984799P 1999-12-09 1999-12-09
US60/169,847 1999-12-09

Publications (2)

Publication Number Publication Date
WO2001041781A2 WO2001041781A2 (fr) 2001-06-14
WO2001041781A3 true WO2001041781A3 (fr) 2002-04-25

Family

ID=22617439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032585 WO2001041781A2 (fr) 1999-12-09 2000-11-30 Inhibiteurs de proteine id pour le traitement de maladies oculaires

Country Status (2)

Country Link
AU (1) AU1935501A (fr)
WO (1) WO2001041781A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011274311A1 (en) * 2010-06-30 2013-01-10 Garvan Institute Of Medical Research Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of Differentiation 1

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371617A2 (fr) * 1988-10-31 1990-06-06 Alcon Laboratories, Inc. Utilisation de stéroides angiostatique pour l'obtention d'un médicament destiné à contrôler l'hypertension oculaire
WO1993010141A2 (fr) * 1991-11-22 1993-05-27 Alcon Laboratories, Inc. Steroïdes angiostatiques
WO1997005283A1 (fr) * 1995-08-01 1997-02-13 Sloan-Kettering Institute For Cancer Research Id UTILISE EN TANT QUE MARQUEUR DIAGNOSTIQUE DANS DES CELLULES TUMORALES
WO1997041844A1 (fr) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinaisons de composes angiostatiques
WO1999032127A1 (fr) * 1997-12-19 1999-07-01 Alcon Laboratories, Inc. Agents angiostatiques et compositions permettant de lutter contre l'hypertension intra-oculaire
US6127178A (en) * 1998-03-20 2000-10-03 The Regents Of The University Of California Apoptotic peptides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371617A2 (fr) * 1988-10-31 1990-06-06 Alcon Laboratories, Inc. Utilisation de stéroides angiostatique pour l'obtention d'un médicament destiné à contrôler l'hypertension oculaire
WO1993010141A2 (fr) * 1991-11-22 1993-05-27 Alcon Laboratories, Inc. Steroïdes angiostatiques
WO1997005283A1 (fr) * 1995-08-01 1997-02-13 Sloan-Kettering Institute For Cancer Research Id UTILISE EN TANT QUE MARQUEUR DIAGNOSTIQUE DANS DES CELLULES TUMORALES
WO1997041844A1 (fr) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinaisons de composes angiostatiques
WO1999032127A1 (fr) * 1997-12-19 1999-07-01 Alcon Laboratories, Inc. Agents angiostatiques et compositions permettant de lutter contre l'hypertension intra-oculaire
US6127178A (en) * 1998-03-20 2000-10-03 The Regents Of The University Of California Apoptotic peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LYDEN D ET AL: "ID1 AND ID3 ARE REQUIRED FOR NEUROGENESIS, ANGIOGENESIS AND VASCULARIZATION OF TUMOUR XENOGRAFTS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 401, 14 October 1999 (1999-10-14), pages 670 - 677, XP002942869, ISSN: 0028-0836 *
ROWE P M: "New class of inhibitors for angiogenesis proposed", THE LANCET, vol. 354, 16 October 1999 (1999-10-16), pages 1362, XP002187042 *

Also Published As

Publication number Publication date
WO2001041781A2 (fr) 2001-06-14
AU1935501A (en) 2001-06-18

Similar Documents

Publication Publication Date Title
WO2001014424A3 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
AU2998000A (en) Method of creating and preserving the identity of non-genetically modified seedsand grains
WO2000038663A3 (fr) Agonistes du recepteur ep4 utilises dans le traitement du syndrome sec
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
TR199802676A3 (tr) Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU7361900A (en) Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
WO2003010291A3 (fr) Traitement de troubles concernant les cellules immunitaires et les cellules b
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
AU6391000A (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2000078327A3 (fr) Agents pour traiter des affections malignes au moyen de la proteine yb-1
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
WO2001041781A3 (fr) Inhibiteurs de proteine id pour le traitement de maladies oculaires
WO2001044235A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
WO2001023522A8 (fr) Compositions et procedes de repression induite par p53 de l'expression de gene
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU3833700A (en) Agents and methods for the control of fungal and bacterial diseases
WO2004041115A3 (fr) Elastases humaines et incontinence urinaire d'effort
AU1393801A (en) Method for the treatment and/or prophylaxis of diseases caused by il-12
WO2003099863A3 (fr) Proteines de liaison a la resistine, elaboration et utilisation correspondantes
WO2001001998A3 (fr) Traitement d'endometriose avec une anti-leucoprotease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP